Global anticoagulant reversal drugs market is likely to exhibit a promising growth curve as far as the short-term outlook is considered. The report will uncover the insights into how the market growth will unfold in the next few years.
Demand Escalates in Anticoagulant Reversal Drugs Market as Bleeding Disorders Continue to Prevail at a Notable Pace
Demand for anticoagulant reversal drugs is primarily driven by an increase in the prevalence of several cardiovascular diseases worldwide, including atrial fibrillation, an increase in gastrointestinal and intracranial hemorrhages, and an increase in the number of elderly people. In accordance with the World Health Organization, 17.9 million people worldwide die from cardiovascular diseases each year. Additionally, heart attacks and strokes account for 85% of these cardiovascular disease deaths. Other key variables that significantly drive the anticoagulant reversal drugs market up, include the approval and introduction of novel medicines, rising bleeding problem prevalence, and a rise in the frequency of indications for anticoagulant therapy. Hemophilia A and B, von Willebrand disease, and blood clots are a few of the bleeding disorders (VWD). The National Hemophilia Foundation (NHF) estimates that between 30,000 and 33,000 Americans have hemophilia, with 60% of those individuals having severe hemophilia. The CDC estimates that 400 newborns are diagnosed with hemophilia A every year.
One in every 100 persons has von Willebrand disease, one of the most prevalent bleeding disorders. Blood clotting is impacted by bleeding disorders, which can lead to excessive bleeding inside and outside the patient's body. This makes anticoagulants more necessary, increasing the need for anticoagulant reversal medications during uncontrolled bleeding. This is expected to accelerate the pace of anticoagulant reversal drugs market. Some drugs, such as blood thinners like heparin, aspirin, and warfarin, can cause bleeding issues. Depending on the anticoagulant agent being used, there is a different risk of bleeding. According to estimates from the National Center for Biotechnology Information (NCBI), between 15% and 20% of warfarin users have bleeding each year. Warfarin-related life-threatening bleeding is thought to occur at a rate of 1-3% annually. As a result, the need for anticoagulant therapy is increasing, which could present new opportunities for anticoagulant reversal drugs.
Anticoagulant Reversal Drugs Market: COVID-19 Impact
Since research on COVID-19 infection is progressing at an increasingly rapid rate, the impact of COVID-19 on the market for anticoagulant reversal medications is anticipated to be substantial. The potential of factor Xa inhibitors in COVID-19 patients are presently being assessed in more than 10 clinical studies, according to the article published in the American Journal of Cardiovascular Drugs in 2020. Additionally, research is being done on methods for administering these medications parenterally to COVID-19 patients who are critically ill. The COVID-19 pandemic is thus anticipated to have both a direct and indirect effect on the market under investigation.
Increase in GI and ICH Hemorrhage Rates to Drive Demand for Anticoagulant Reversal Drugs Market
The bulk of bleeding cases in patients receiving direct oral anticoagulants (DOAC) are intracranial hemorrhages (ICH); the annual prevalence rate ranges between 8% and 18%. More than 50% of significant bleeding events are GI hemorrhages, the most common type. The high frequency of GI hemorrhages associated with DAOC can be attributed to poor GI absorption, which raises local drug levels. With the anticoagulant's impact, the high occurrence of bleeding events has necessitated using anticoagulant reversal medicines to control bleeding. During the predicted period, this is expected to boost the growth of the global anticoagulant reversal drugs market.
Rising Necessity of Anticoagulants Further Paves the Way for Anticoagulant Reversal Drugs Market
The increased demand that can be employed in the event of uncontrolled bleeding, is predicted to fuel the growth of anticoagulant reversal drugs market during the duration of the forecast. Some of the most common bleeding illnesses are blood clots, von Willebrand disease, and hemophilia A and B bleeding disorders. About one out of every hundred persons suffer from Von Willebrand disease, a fairly common bleeding disorder. Disorders that cause bleeding can stop blood from clotting normally and result in the patient's body bleeding out of control. According to the National Hemophilia Foundation, there are between 30,000 and 33,000 hemophiliacs in the United States, with acute hemophilia accounting for about 60% of cases (NHF). According to the National Hemophilia Foundation, there are between 30,000 and 33,000 hemophiliacs in the United States, with acute hemophilia accounting for about 60% of cases (NHF).
Higher Costs Hamper Anticoagulant Reversal Drugs Market Growth
The high cost of anticoagulant reversal drugs is anticipated to act as a limitation to the growth of anticoagulant reversal drugs market during the projected period. The dose of 4-F PCC (Kcentra) used to treat patients who have experienced bleeding as a side effect of apixaban or rivaroxaban is 50 units/k, as recommended by the American College of Cardiology. Given that its average wholesale price is US$2.90 per unit, the expense of treating a patient weighing 100 kg would be close to US$14,500. Regional and local players are considering expanding their presence in the anticoagulant reversal therapy market by introducing generic medications in response to this high-cost concern.
Idarucizumab to Dominate Anticoagulant Reversal Drugs Market Based on Increased Efficacy
Throughout the forecast period, the idarucizumab segment is anticipated to experience the highest growth in the worldwide anticoagulant reversal drugs market. Idarucizumab's high-income creation in important regions is to blame for this. Idarucizumab from Boehringer Ingelheim Pharmaceuticals has been approved as an anticoagulant reversal drug for people on Pradaxa following urgent surgery or life-threatening bleeding. With the accessibility of these anticoagulation reversal medications, medical professionals and patients are more inclined to choose these therapeutic choices, driving up demand for anticoagulant reversal therapies and thus driving up demand for anticoagulant reversal drugs. The medicine is highly in demand because of its excellent specificity and efficacy. A product's swift clearance in many important countries is proving to be a significant growth driver for this market due to its enormous potential.
With Increased Use During Surgeries, Hospital Pharmacies Dominate Anticoagulant Reversal Drugs Market
Hospital pharmacies dominate the anticoagulant reversal drugs market and had the biggest share over the forecasted period. Hospitals are the main locations for diagnosing and treating various kinds of bleeding problems, which is why this is the case. Emergencies with uncontrolled bleeding are another factor driving the category. With the increased use of anticoagulant medications during surgical operations to manage excessive bleeding and life-threatening hemorrhage disorders, the market is anticipated to develop rapidly. Furthermore, these medications are frequently accessible in hospital pharmacies because they are employed in emergency treatments.
North America to Acquire a Major Value Share in Anticoagulant Reversal Drugs Market
North America held the greatest revenue share in anticoagulant reversal drugs market and is anticipated to keep the lead for the entire forecast period. With the elements including the availability of direct reimbursement policies and the region's cutting-edge healthcare infrastructure, the industry under study in North America has experienced rapid expansion. The two main factors driving its expansion are the high level of healthcare spending and the favorable healthcare reimbursement laws for pricey drugs. The quick availability of these reversal drugs in times of urgent necessity is another important aspect driving up demand in the local market.
With the USFDA's accelerated drug approval initiative and the Centers for Disease Control and Prevention's launch of numerous blood disorder prevention programs and awareness workshops, which are expected to fuel anticoagulant reversal drugs market growth in this region, the US holds the largest market share in the North American region. The market under study is also driven by the high frequency of cardiovascular illnesses in the United States. The American Heart Association estimates that in 2019, there will be 720,000 new and 335,000 recurrent coronary incidents among 1,055,000 people in the United States, resulting in one American having a myocardial infarction every 40 seconds. The market for anticoagulant reversal medications is expected to expand significantly in North America throughout the forecast period, given the aforementioned causes.
During the projected period, Asia Pacific is anticipated to grow at the fastest rate. The presence of a sizable target audience in developing nations like China and India has considerably aided the expansion of the regional industry. The demand for anticoagulant reversal medications in this region is also being driven by rising awareness and an increase in the prevalence of bleeding disorders. Atrial fibrillation (AF) is a persistent arrhythmia linked to an elevated mortality and stroke rate in Asian populations. As Asia's population rapidly ages, it is predicted that by 2050, approximately 72 million people in the region will have AF. With the rise in people suffering from conditions including strokes, atrial fibrillation, and other cardiopulmonary disorders, the region with the fastest growth rate in the next years will be the Asia Pacific. Current anticoagulant medication trials in this region will further fuel the expansion of the anticoagulant reversal drugs market here.
Global Anticoagulant Reversal Drugs Market: Competitive Landscape
In October 2021, Alveron Pharma BV raised an additional EUR 3.9 million to fund the further development of OKL-1111, a first-in-class medication for treating anticoagulant-related bleeding. Thuja Capital, Waterman Ventures, and Oost NL contributed to raising money, including a loan from Rijksdienst Voor Ondernemend Nederland (RVO). The new investment will go toward the OKL-1111 program, including a first-in-man trial, which is set to begin in Q3 2022. In July 2020, Portola Pharmaceuticals, Inc announced that the Centers for Medicare & Medicaid Services (CMS) had approved a new permanent J-code for Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], allowing for coverage in the hospital outpatient setting. J7169 (Injection, coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa), 10 mg), which was made public online in the Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions by the Centers for Medicare & Medicaid Services (CMS), and it will take the place of the previously issued interim C-code on July 1, 2020.
A few of the players in anticoagulant reversal drugs market include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.
Regional Classification of the Global Anticoagulant Reversal Drugs Market is Described Below:
Middle East and Africa
*Regions and countries are subject to change based on data availability.
Key Elements Included In The Study: Global Anticoagulant Reversal Drugs Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.View Methodology